The fundamental principle that physical and mental well-being represent our most valuable assets is currently undergoing a cynical transformation within Jammu and Kashmir. While higher socio-economic status typically correlates with better health prospects, the local reality has shifted toward a predatory “wealth is health” paradigm, where financial extraction is prioritized over patient recovery. This shift is characterized by a systemic erosion of trust, as the healthcare sector’s responsibility to provide care is increasingly overshadowed by treatment protocols designed to accumulate wealth at the expense of those suffering. The current state of affairs represents a “tsunami” for patients who find themselves pushed to the brink, and in many instances, condemned to death due to a lack of financial resources.
The economic burden on households is exacerbated by a retail pharma market where the actual cost of medicine remains invisible, hidden behind maximum retail prices loaded with margins ranging from 100% to 1000%. Even drugs under the Drug Price Control Order are frequently sold at two to ten times their original cost, despite regulations limiting profit margins to 16%. This medical inflation outpaces general inflation, acting as a termite on household savings and forcing families to sell assets or borrow heavily to manage treatment expenses. This financial imbalance is particularly devastating for those battling cancer, where the cost of innovative therapies often exceeds the annual income of the patient, leading many to succumb midway through their treatment protocol for want of finances rather than the disease itself.
Beyond the financial crisis lies a deeper crisis of ethics and professional conduct. A section of the medical fraternity, described as “holy entrepreneurs” or “Corona Exploitation Opportunists,” capitalized on the COVID-19 pandemic to earn tax-free profits while brazenly violating safety guidelines at private clinics. The sacrosanct doctor-patient relationship has weakened as senior consultants are increasingly viewed as “medico-marketers” who maintain close ties with pharmaceutical companies and government circles to protect their interests. This behavior forces patients to doubt treatment protocols and leaves junior medical staff to face the public’s fury for systemic failures they did not create.
To address these critical issues, a comprehensive strategy is required that emphasizes accountability and affordability. Dr. Mohammad Sultan Khuroo’s ten-point agenda provides a necessary roadmap, stressing on the need for population-based cancer registries, intensive public awareness programs, and the decentralization of cancer management beyond specialized oncology units. Furthermore, the government must take concrete steps to curb unfair trade practices, conduct scrutiny of private diagnostic facilities, and implement drastic tax cuts on life-saving medicines. Ultimately, the health department and regional planners must treat the current state of the healthcare sector as a menace to society, ensuring that every rupee spent facilitates a system where the lives of people truly matter more than profit margins.
